



Cite this: *Org. Biomol. Chem.*, 2015, **13**, 4931

Elucidation of several neglected reactions in the GC–MS identification of sialic acids as heptafluorobutyrate calls for an urgent reassessment of previous claims†

Paola Rota,^{*a} Luigi Anastasia^{b,c} and Pietro Allevi^a

The current analytical protocol used for the GC–MS determination of free or 1,7-lactonized natural sialic acids (Sias), as heptafluorobutyrate, overlooks several transformations. Using authentic reference standards and by combining GC–MS and NMR analyses, flaws in the analytical protocol were pinpointed and elucidated, thus establishing the scope and limitations of the method. It was demonstrated that (a) Sias 1,7-lactones, even if present in biological samples, decompose under the acidic hydrolysis conditions used for their release; (b) Sias 1,7-lactones are unpredicted artifacts, accidentally generated from their parent acids; (c) the *N*-acetyl group is quantitatively exchanged with that of the derivatizing perfluorinated anhydride; (d) the partial or complete failure of the Sias esterification-step with diazomethane leads to the incorrect quantification and structure attribution of all free Sias. While these findings prompt an urgent correction and improvement of the current analytical protocol, they could be instrumental for a critical revision of many incorrect claims reported in the literature.

Received 14th January 2015,
Accepted 17th March 2015

DOI: 10.1039/c5ob00081e

www.rsc.org/obc

Introduction

N-Acetylneuraminic acid **1a** (Neu5Ac), *N*-glycolylneuraminic acid **2** (Neu5Gc), and 2-keto-3-deoxy-*D*-glycero-*D*-galactonoic acid **3** (KDN) (Fig. 1) are the most representative members of the sialic acid (Sias) family, a group of more than sixty structurally distinct acidic monosaccharides that are present in various natural glycoconjugates.¹

Sias are usually linked to the non-reducing end of the carbohydrate chain with an α -acetalic bond and are involved in many key biological processes and pathologies, including cancer and heart diseases.^{1,2}

Because of the importance and diversity of Sias, efforts have been made to set-up suitable analytical methods for their identification in biological samples of different origin.¹

The approach that more significantly contributed to identify and map the Sias family relies on the derivatization of their hydroxyls as heptafluorobutyrate (HFBs) before GC–MS analy-




Fig. 1 Chemical structures of the most representative Sias and of the corresponding 1,7-lactones.

^aDepartment of Biomedical, Surgical and Dental Sciences, University of Milan, via Saldini 50, I-20133 Milan, Italy. E-mail: paola.rota@unimi.it;
Fax: +390250316040; Tel: +390250316047

^bDepartment of Biomedical Sciences for Health, University of Milan, Segrate Milan, Italy

^cLaboratory of Stem Cells for Tissue Engineering, IRCCS Policlinico San Donato, San Donato, Milan, Italy

† Electronic supplementary information (ESI) available. See DOI: 10.1039/c5ob00081e

sis.^{1c,3} For instance, the application of this method recognized about fifty different sialic acids, more than fifteen of which are new compounds, including the 1,7-lactones **4a–c** of Neu5Ac and the 1,7-lactone **5** of Neu5Gc as new members of the Sias family (Fig. 1).^{1c,3b,g,h} Owing to their stereochemistry, a surprising (yet unfortunately overlooked) feature of the allegedly newly identified natural 1,7-lactones was that they could only be linked to glycoconjugates with an unusual β -glycosidic

bond. Nonetheless, this did not raise any concern, and several 1,7-lactones of Neu5Ac were identified in biological samples and reported to have crucial roles in a number of biological processes and pathologies.^{3b,3i,4} For instance, **4a** has been described as a high-affinity ligand for interleukin 4,⁴ and it was found overexpressed in various cancer cells³ⁱ and in polycythemia vera, a malignant disorder of hematopoietic stem cells.^{3b}


The crucial steps for the identification of these 1,7-lactones in glycoconjugates by GC-MS are acidic hydrolysis of their acetalic bonds, followed by a derivatization reaction with heptafluorobutyric anhydride (HFBA), which is sometimes preceded by diazomethane treatment.^{1c,3a,h} The initial step relies on the assumption that these 1,7-lactones are stable under acidic conditions. However, during our previous studies on Sias,⁵ we developed the synthesis of the free 1,7-lactones **4a** and **5^{5g-i}** based on the ability of Neu5Ac **1a** to form protected 1,7-lactones under acylation conditions,⁶ and observed their low stability in protic solvents. This unfavorable feature hindered their isolation and/or purification from aqueous reaction mixtures,^{5g} and posed some initial doubts about the soundness of the analytical protocol currently used for their identification.^{1c,3} Moreover, once we synthesized **4a** in the pure form and unequivocally assigned its structure by NMR, we subjected it to HFBA derivatization. Surprisingly, we recorded different mass spectra from the one previously reported,^{1c} which was obtained by subjecting a biological sample that supposedly contained the same lactone **4a** to the hydrolysis-derivatization analytical protocol.^{1c,3}

Altogether this evidence started to support the notion that 1,7-lactones **4a-c** and other natural Sias could not be correctly identified with the current analytical methodology.^{1c,3} While this called for an extensive revision of the protocol, it also prompted for an urgent in-depth reexamination of the behavior of the 1,7-lactones **4a-c**, of their parent acids **1a-c**, and of other analogs under the same reaction conditions used for their identification. This step was mandatory in order to fix all the incorrect claims reported in the literature,^{1c,3} which were based on wrong structural assignments.

Results and discussion

Initially, we performed the synthesis of **4a^{5g-i}** and of its new acetylated congeners **4b, c** by adapting and expanding our previous synthetic protocol,^{5g-i} using the lactone **7a** as a key intermediate as depicted in Scheme 1. In particular, we accomplished the synthesis of the acetylated 1,7-lactones **4b-c** by elaboration of the intermediate lactone **7a**, performing, in the final step, the reductive regeneration of its acetal group, under anhydrous conditions.

Then, we executed some hydrolytic stability tests on authentic samples of compounds **4a-c**. Lactones **4a, b^{5f}** were rather unstable in aqueous solution, as they completely decomposed within 24 hours at 23 °C by simply standing in D₂O, as revealed by NMR analyses. Only **4c** survived for almost a week when dissolved in water at 23 °C.




Scheme 1 Syntheses of lactones **4a-c**. Reagents and conditions: (i) CbzCl, Et₃N, THF-DMF, 0 °C → 23 °C, 30 min, 82%; (ii) (MeO)₃CMe, PPTS, THF, 23 °C, 1 h; (iii) H₂, Pd/C, AcOEt, 25 °C, 3 h; (iv) Me₂C(OMe)₂, p-TSA, DMF, 23 °C, 1 h; (v) Ac₂O, Py, DMAP, 23 °C, 1 h; and (vi) moist CF₃COOH, CH₂Cl₂, 40 °C, 1 h.

Moreover, as we anticipated, all of them decomposed under the hydrolytic treatment (2 M aqueous acetic acid solution, at 80 °C for 90 min) used for their release from natural glycoconjugates.^{1c,3b,g,h} The decomposition was complete for **4a** and **4b** and partial, but relevant (35%), for **4c**. This evidence unambiguously reveals that Neu5Ac 1,7-lactones **4a-c**, even if present in biological samples of glycoconjugates, cannot properly survive to the acidic hydrolysis required for their release. Nonetheless, as they have been found by GC-MS in biological samples after acidic hydrolysis, we speculated that they could be unintentionally formed during the acylation of their parent acids **1a-c** with HFBA. If that was the case, based on our previous work on the *N*-transacylation of acetamides,^{5d,5e} the protected 1,7-lactones formed during the derivatization treatment with HFBA (in CH₃CN at 150 °C for 5 min), should have the structure of the *N*-transacylated congeners **8a-c** (Scheme 2).

We verified this hypothesis by observing the reaction of suitable amounts (15–30 mg scale) of the Sias **1a-c** and of the corresponding lactones **4a-c** with HFBA. Remarkably, under the reported derivatization conditions, we obtained the same protected *N*-transacylated 1,7-lactones **8a-c** (Scheme 2). This was evident from the GC-MS and NMR analyses of the crude reaction products that clearly demonstrated the lack of any acetamido group in the obtained compounds, which were in fact completely acylated. However, we were surprised to observe that their EI-MS fragmentation patterns (Fig. 2) were different from those reported for the alleged Neu5Ac 1,7-lactones **4a-c**.^{1c}

In contrast, mass spectra were superimposable (for **8a, b**) or very similar (for **8c**) to those reported for acids **1a-c**, which were analyzed as HFBs, after esterification with diazomethane, according to the protocol.^{1c}

In order to understand and clarify these discrepancies, we first excluded that the 1,7-lactones resulting from an inner



Scheme 2 Syntheses of heptafluorobutyric lactones **8a–c**. Reagents and conditions: (i) HFBA, MeCN, 150 °C, 5 min.




Fig. 2 EI mass spectra of lactones **8a–c** obtained by derivatization (HFBA, MeCN, 150 °C, 5 min) of the corresponding acids **1a–c** or of the lactones **4a–c** (see ESI†).

lactonization of the allegedly formed methyl esters. To this purpose, we subjected authentic and pure samples of Neu5Ac **1a–c** methyl esters to the same GC–MS analysis as HFBS. However, none of the obtained products (or byproducts) showed an EI–MS profile similar to those we obtained for the authentic 1,7-lactones **4a–c** (Fig. 3).

Based on our data, we considered highly plausible that the described^{1c,3} esterification step with diazomethane was either





Fig. 3 EI mass spectra obtained after derivatization (HFBA, MeCN, 150 °C, 5 min) of the methyl esters of sialic acids **1a–c**. A and B represent the mass spectra of peaks at 7.80 and 8.84 min of the derivative of methyl ester of **1a**; C represent the mass spectrum of peak at 9.00 min of the derivative of methyl ester of **1b**; D represent the mass spectrum of peak at 8.51 min of the derivative of methyl ester of **1c** (see ESI†).

partially or totally unsuccessful, and that the unreacted Sias **1a–c** underwent an unforeseen lactonization in the successive treatment with HFBA. This forms the 1,7-lactones **8a–c**, incorrectly identified in the reported experiments.^{1c,3} In fact, neglecting both the unsuccessful esterification with diazomethane and the successive transesterification with HFBA, induced a massive misinterpretation of the GC–MS spectra, resulting in extensive errors also in the identification and quantification of free Sias present in the biological samples.^{1c,3}

Finally, in order to complete this intricate puzzle, we had to establish the nature of the compounds responsible for the mass spectral fragmentations erroneously attributed to the 1,7-lactones **4a–c** HFBS.^{1c,3b} A conceivable explanation appeared to be that they had the structure of untransacylated congeners of **8a–c**, which are the unexpected byproducts of HFBA treatment. In fact, according to the mechanism of the *N*-transacylation of normal amides, treatment of the Sias **1a–c** (or of the lactones **4a–c**) with HFBA should initially form the lactonic acetamides **9a–c** (Scheme 3), which are in equilibrium with the corresponding imides **10a–c** in the sealed reaction vessel.^{5d}

These imides, under the conditions described in the protocol (heating at 150 °C for 5 min), should irreversibly form the



Scheme 3 Formation and *N*-transacylation of lactones **8a–c**. Reagents and conditions: (i) HFBAA excess, MeCN, 150 °C, 5 min.




Fig. 4 EI mass spectra of lactones **9a–c** obtained by derivatization with HFBAA at 23 °C of the acids **1a–c** and of the lactones **4a–c** (see ESI†).

N-transacylated amides **8a–c**, in nearly quantitative yields. In contrast, the imides **10a–c** should at least partially survive when the reaction is performed at lower temperatures and/or for a shorter reaction time. During the work-up of the reaction mixtures (evaporation of the solvent and of the HFBAA excess), these imides should regenerate the untransacylated lactones **9a–c**, in variable yields. If that was the case, variable amounts of the acetamides **9a–c** should be present in the final reaction mixture, as a consequence of the equilibrium shift in favor of the HFBS **9a–c**. To test this hypothesis, we treated Neu5Ac **1a–c** and lactones **4a–c** with HFBAA at lower temperature (100–120 °C, for 5 min).^{1c} As we expected, GC–MS analyses of the reaction mixtures revealed that each *N*-transacylated lactone **8a–c** was accompanied by a second minor compound showing a fragmentation pattern (Fig. 4) superimposable, or very similar, to that of the reported HFBS of the 1,7-lactone **4a–c**.^{1c}

The assignment of the correct structures, **9a–c**, to the obtained by-products, which were erroneously considered unesterified at the anomeric hydroxyl, was unequivocally confirmed by NMR analyses of authentic samples which were synthesized on a 15–30 mg scale in reactions with HFBAA performed at 23 °C.

Experimental

Materials and reagents

All chemicals and solvents used were of analytical grade and purchased from Sigma-Aldrich (St. Louis, MO, USA). The sialic acid **1a** and its methyl ester were from Sigma-Aldrich. The acetylated Sias **1b** and **1c**⁷ and the methyl ester of **1b**⁸ were prepared according to the indicated literature reports. The methyl ester of acid **1c** was obtained by treatment with diazomethane of the parent acid as a white solid glass showing: elemental analysis (Found: C, 47.2; H 6.15; N 3.5; C₁₆H₂₅NO₁₁ requires C, 47.2; H 6.2; N 3.4%); δ_H (CD₃OD) 5.31 (1H, ddd, $J_{4,3b}$ 11.3, $J_{4,5}$ 10.1, $J_{4,3a}$ 5.0, 4-H), 4.36 (1H, dd, $J_{9a,9b}$ 11.6, $J_{9a,8}$ 2.4, 9a-H), 4.17 (1H, dd, $J_{6,5}$ 10.6, $J_{6,7}$ 1.2, 1H, H-6), 4.15–4.08 (2H, overlapping, 9b-H- and 5-H), 3.89 (1H, ddd, $J_{8,7}$ 9.1, $J_{8,9b}$ 6.3, $J_{8,9a}$ 2.4, 8-H), 3.78 (3H, s, COOCH₃), 3.50 (1H, dd, $J_{7,8}$ 9.1, $J_{7,6}$ 1.2, 7-H), 2.30 (1H, dd, $J_{3a,3b}$ 12.7, $J_{3a,4}$ 5.0, 3a-H), 2.06 (3H, s, OCOCH₃ at C-9), 2.02 (3H, s, OCOCH₃ at C-4), 1.97–1.93 (4H, overlapping, 3b-H and NHCOCH₃); δ_C (CD₃OD) 174.3, 173.1, 172.2, 171.4 (4C, NHCOCH₃, OCOCH₃ at C-4, OCOCH₃ at C-9 and C-1), 96.5 (C-2), 71.7, 71.1, 70.2, 69.5 (C-4, C-6, C-7 and C-8), 67.8 (C-9), 53.3 (COOCH₃), 51.2 (C-5), 37.7 (C-3), 22.6 (NHCOCH₃), 20.9 and 20.8 (2C, OCOCH₃ at C-4 and OCOCH₃ at C-9); MS (ESI positive) m/z 430.4 [M + Na]⁺.

The aqueous solutions of 2 M CH₃COOD were taken from a stock solution prepared by the addition of (CH₃CO)₂O (945 μ L, 10.0 mmol) to cold D₂O (8.0 mL) and dilution with D₂O to 10.0 mL.

General remarks

Nuclear magnetic resonance spectra were recorded at 303 K on a Bruker AM-500 spectrometer equipped with a 5 mm inverse-geometry broadband probe and operating at 500.13 MHz for ¹H and 125.76 MHz for ¹³C. Chemical shifts are reported in parts per million (ppm, δ units) and are referenced for ¹H spectra, to a solvent residue proton signal (δ 7.26, 3.31, 2.50 and 1.94 ppm, respectively for CDCl₃, CD₃OD, (CD₃)₃SO and CD₃CN solutions) and for ¹³C spectra, to a solvent carbon signal (central line at δ 77.0, 49.05, 39.43 and 1.24 ppm, respectively for CDCl₃, CD₃OD, (CD₃)₃SO and CD₃CN solutions). The ¹H and ¹³C resonances were assigned by ¹H–¹H (COSY) and ¹H–¹³C (HSQC and HMBC) correlation 2D experiments. ¹H NMR data are tabulated in the following order: number of protons, multiplicity (s, singlet; d, doublet; br s, broad singlet; m, multiplet), coupling constant(s) in hertz, assignment of proton(s). GC–MS analysis was performed by Finnigan TraceGC-ultra chromatograph coupled with a Finnigan Trace DSQ mass spectrometer (Thermo Scientific, Waltham, MA, USA). A capillary column (25 m \times 0.25 mm i.d.) with a HP-5MS bonded stationary phase film (0.25 μ m thickness, Agilent Technologies, USA) was used. The inlet temperature was maintained at 260 °C. The column oven was held at 100 °C for 1 min and then programmed from 100 to 270 °C at 20 °C min⁻¹. The MS transfer line was set to 250 °C. Helium at a constant flow-rate of 1 mL min⁻¹ was used as a carrier gas. The injection mode was split (split ratio, 50:1; split flow,

50 mL min⁻¹) and the injection volume was 1 μ L. The analyses were performed in the EI mode (ionization energy 70 eV; source temperature 200 °C). Optical rotations were performed on a polarimeter equipped with a 1 dm tube; $[\alpha]_D$ values are given in 10⁻¹ deg cm² g⁻¹ and the concentrations are given in g per 100 mL. ESI mass spectra were recorded using a Finnigan LCQ_{deca} quadrupole ion trap mass spectrometer (Finnigan Thermo Quest, San Jose, CA, USA) equipped with an electrospray ion (ESI) source and the spectra were collected in continuous flow mode by connecting the infusion pump directly to the ESI source. The reactions were monitored, when possible, by thin-layer chromatography (TLC) carried out on 0.25 mm E. Merck silica gel plates (60 F254) using UV light, 50% sulphuric acid or 0.2% ninhydrin in ethanol and heat as the developing agent. E. Merck 230–400 mesh silica gel was used for flash column chromatography.

Preparation of 2-benzyloxycarbonyl-*N*-acetylneuraminic acid 1,7-lactone **7a**

Sialic acid **1a** (900 mg, 2.91 mmol), dissolved in DMF (10 mL) at 60 °C, under stirring, was cooled at 0 °C and diluted with THF (8 mL). Then CbzCl (1.04 mL; 7.28 mmol, 2.5 eq.) in THF (4 mL) was added in a single portion, followed by Et₃N (1.20 mL; 8.73 mmol, in a single addition). The mixture was then stirred for 30 min at 23 °C. After this, methanol (2 mL) was added dropwise and the stirring was continued for 15 min. Evaporation of the solvent under reduced pressure (22 mmHg and then at 10⁻¹ mmHg) afforded a crude residue, which, after purification by flash chromatography (eluting with AcOEt–MeOH, 9 : 1, v : v), afforded the pure Neu5Ac 1,7-lactone **6** (1.01 g; 82%) as a white solid: mp 122–124 °C. The other physico-chemical properties are identical to those reported. This procedure uses a reduced amount of benzyloxycarbonyl chloride (CbzCl) in the synthesis of the 1,7-lactones to address issues relating to the required excess of CbzCl.⁵ⁱ

Preparation of 9-*O*-acetyl-*N*-acetylneuraminic acid 1,7-lactone **4b**

Synthesis of 9-*O*-acetyl-2-benzyloxycarbonyl-*N*-acetylneuraminic acid 1,7-lactone (7b**).** Trimethyl orthoacetate (110 μ L) and pyridinium *p*-toluenesulfonate (10 mg) were added in a sequence to a solution of the 2-benzyloxycarbonyl 1,7-lactone **7a** (200 mg, 0.480 mmol) dissolved in tetrahydrofuran (5 mL) and the solution was stirred at 25 °C for 1 h. Then water (0.2 mL) was added and the solution stirred for 30 min before neutralization with a weak basic resin (IRA-67), filtered and the solvent evaporated under reduced pressure to afford a crude residue. The residue was purified by column chromatography on silica gel (eluting with AcOEt–MeOH, 95 : 5, v/v), to afford the pure 9-*O*-acetyl-2-benzyloxycarbonyl-*N*-acetylneuraminic acid 1,7-lactone **7b** (182 mg, 85%) as a glass: $[\alpha]_D^{20}$ +13.1 (*c* 1 in MeOH); elemental analysis (Found: C, 53.9; H, 5.4; N, 2.95; C₂₁H₂₅NO₁₁ requires C, 54.0; H, 5.4; N, 3.0%); δ_H (CD₃OD) 7.43–7.40 (5H, overlapping, Ph), 5.24–5.16 (2H, AB system, CH₂Ph), 4.63 (1H, br s, 6-H), 4.46 (1H, d, *J*_{7,8} 9.1, 7-H), 4.41 (dd, *J*_{9a,9b} 11.6, *J*_{9a,8} 1.7, 1H, 9a-H), 4.24 (1H, dd, *J*_{9b,9a}

11.6, *J*_{9b,8} 4.7, 9b-H), 4.19–4.14 (1H, 1H, 8-H), 4.12–4.09 (1H, br s, 4-H), 4.65–4.35 (1H, br s, H-5), 2.29 (1H, dd, *J*_{3a,3b} 13.9, *J*_{3a,4} 3.1, 3a-H), 2.11 (1H, br d, *J*_{3a,3b} 13.9, 3b-H), 2.11 (3H, s, OCOCH₃ at C-9), 2.01 ppm (3H, s, NHCOCH₃); δ_C (CD₃OD) 172.9 (2C, NHCOCH₃ and OCOCH₃ at C-9), 167.6 (C-1), 153.5 (PhCH₂OCOO), 136.3, 129.8, 129.7, 129.4 (Ph), 94.9 (C-2), 80.0 (C-7), 73.2 (C-6), 71.4 (PhCH₂OCOO), 69.6 (C-8), 67.4 (C-4), 66.2 (C-9), 52.5 (C-5), 37.0 (C-3), 22.5 (NHCOCH₃), 20.8 (OCOCH₃ at C-9); MS (ESI positive) *m/z* 490.1 [M + Na]⁺.

Synthesis of 9-*O*-acetyl-*N*-acetylneuraminic acid 1,7-lactone (4b**).** The 1,7-lactone **7b** (300 mg, 0.64 mmol) was dissolved in ethyl acetate (65 mL) and hydrogenated in the presence of 10% Pd/C (30 mg) for 3 h. Then the catalyst was filtered on a pad of Celite and washed with anhydrous THF. The removal of the solvent, under reduced pressure, afforded the 9-*O*-acetyl-*N*-acetylneuraminic acid 1,7-lactone **4b** (200 mg, 95%) as an amorphous white solid that completely decomposes on standing at room temperature for one month and shows: $[\alpha]_D^{20}$ +13.1 (*c* 1 in THF); elemental analysis (Found: C, 46.8; H, 5.8; N, 4.1; C₁₃H₁₉NO₉ requires C, 46.85; H, 5.75; N, 4.2%); δ_H (DMSO-*d*₆): 8.24 (1H, d, *J*_{NH,5} 7.9, NHCOCH₃), 7.35 (1H, s, OH at C-2), 5.63 (1H, d, *J*_{OH,8} 6.6, OH at C-8), 5.47 (1H, d, *J*_{OH,4} 2.3, OH at C-4), 4.35–4.27 (2H, overlapping, 6-H and 9a-H), 4.20 (1H, d, *J*_{7,8} 8.9 Hz, 7-H), 3.95 (1H, dd, *J*_{9b,9a} 11.6, *J*_{9b,8} 5.9, 9b-H), 3.81 (1H, br s, 4-H), 3.80–3.72 (2H, overlapping, 8-H and 5-H), 2.04 (3H, s, OCOCH₃), 1.97 (1H, dd, *J*_{3a,3b} 13.8, *J*_{3a,4} 2.9, 3a-H), 1.87 (3H, s, NHCOCH₃), 1.81 (1H, br d, *J*_{3b,3a} 13.8, 3b-H); δ_C (DMSO-*d*₆) 170.3 (1C, OCOCH₃), 169.0 (C-1), 168.9 (NHCOCH₃), 90.4 (C-2), 77.7 (C-7), 70.1 (C-8), 68.4 (C-6), 65.9 (C-4), 64.8 (C-9), 50.2 (C-5), 30.3 (C-3), 22.3 (NHCOCH₃), 20.7 (OCOCH₃); MS (ESI negative) *m/z* 332.6 [M – H]⁻.

Preparation of 4,9-*O*-diacetyl-*N*-acetylneuraminic acid 1,7-lactone **4c**

Synthesis of 8,9-isopropylidene-2-benzyloxycarbonyl-*N*-acetylneuraminic acid 1,7-lactone (7c**).** To a solution of 2-benzyloxycarbonyl *N*-acetylneuraminic acid 1,7-lactone **7a** (200 mg, 0.480 mmol) in DMF (2.0 mL), 2,2-dimethoxypropane (580 μ L, 4.8 mmol) was added followed by *p*-toluenesulfonic acid (2 mg). The mixture was stirred at 23 °C for 1 h and then was neutralized with a weak basic resin (IRA-67) and filtered. The solvent was then evaporated, under reduced pressure, and the residue was chromatographed on silica gel (eluting with AcOEt–hexane, 95 : 5, v/v) to afford the 1,7-lactone **7c** (174 mg, 81%) as a glass; $[\alpha]_D^{20}$ 19.2 (*c* 1 in MeOH); elemental analysis (Found: C, 56.8; H, 5.9; N, 3.1; C₂₂H₂₇NO₁₀ requires C, 56.8; H, 5.85; N, 3.0%); δ_H (CD₃OD) 7.40–7.32 (5H, overlapping, Ph), 5.20–5.15 (2H, AB system, CH₂Ph), 4.49 (1H, br s, 6-H), 4.43 (1H, ddd, *J*_{8,7} 9.4, *J*_{8,9b} 5.7, *J*_{8,9a} 4.2, 8-H), 4.30 (1H, d, *J*_{7,8} 9.4, 7-H), 4.16–4.06 (3H, overlapping, 9a-H, 9b-H and 4-H), 4.01–3.99 (1H, br s, 5-H), 2.27 (1H, dd, *J*_{3a,3b} 13.9, *J*_{3a,4} 3.4, 3a-H), 2.11 (1H, d, *J*_{3a,3b} 13.9, 3a-H), 1.99 (3H, s, NHCOCH₃), 1.40 (1H, s, C(CH₃)₂), 1.34 (1H, s, C(CH₃)₂); δ_C (CD₃OD) 172.9 (1C, NHCOCH₃), 167.5 (C-1), 153.5 (PhCH₂OCOO), 136.3, 129.8, 129.7, 129.4 (Ph), 111.2 (1C, C(CH₃)₂), 94.9 (C-2), 80.7 (C-7), 75.6 (C-6), 73.6 (PhCH₂OCOO), 71.4 (C-8), 67.8 (C-4), 67.3 (C-9),

52.4 (C-5), 37.0 (C-3), 27.4 (1C, C(CH₃)₂), 25.5 (1C, C(CH₃)₂), 22.4 (NHCOCH₃); MS (ESI positive) *m/z* 488.1 [M + Na]⁺.

Synthesis of 8,9-isopropylidene-4-acetyl-2-benzoyloxycarbonyl-*N*-acetylneuraminic acid 1,7-lactone (7d). Protected 1,7-lactone **7c** (240 mg, 0.516 mmol), dissolved in pyridine (0.6 mL), was treated with acetic anhydride (150 μL, 1.50 mmol) containing a trace of 4-dimethylamino pyridine. After 1 h at 23 °C, a methanol solution was added and concentrated under reduced pressure. Ice cold water was added to the crude residue and extracted with ethyl acetate. After drying with anhydrous sodium sulfate, the organic layer was filtered and the solvent evaporated under reduced pressure to afford a crude residue that was chromatographed on silica gel (eluting with AcOEt–hexane, 95 : 5, v/v) to afford the compound **7d** (230 mg, 87%) as a glass; [α]_D²⁰ + 14.2 (*c* 1 in MeOH); elemental analysis (Found: C, 56.7; H, 5.8; N, 2.7; C₂₄H₂₉NO₁₁ requires C, 56.8; H, 5.8; N, 2.8%); δ_H (CDCl₃) 7.39–7.30 (5H, overlapping, Ph), 6.30 (1H, d, *J*_{NH,5} 8.2, NHCOCH₃), 5.20–5.14 (2H, AB system, CH₂Ph), 5.08 (1H, br s, 1H, 4-H), 4.55 (1H, s, 6-H), 4.51 (1H, ddd, *J*_{8,7} 9.7, *J*_{8,9b} 5.4, *J*_{8,9a} 4.0, 8-H), 4.22–4.14 (4H, overlapping, 9a-H, 9b-H, 7-H and 5-H), 2.36 (1H, br d, *J*_{3a,3b} 14.9, 3a-H), 2.16 (1H, dd, *J*_{3a,3b} 13.9, *J*_{3b,4} 3.7, 3a-H), 2.04 (3H, s, OCOCH₃ at C-4), 2.01 (3H, s, NHCOCH₃), 1.42 (1H, s, C(CH₃)₂), 1.35 (1H, s, C(CH₃)₂); δ_c (CD₃OD) 169.4 (1C, OCOCH₃ at C-4), 169.0 (1C, NHCOCH₃), 164.4 (C-1), 151.7 (PhCH₂OCOO), 134.0, 128.9, 128.7, 128.3 (Ph), 110.2 (1C, C(CH₃)₂), 93.1 (C-2), 79.2 (C-7), 73.6 (C-6), 72.3 (PhCH₂OCOO), 70.7 (C-8), 67.5 (C-4), 66.8 (C-9), 48.3 (C-5), 33.2 (C-3), 27.1 C(CH₃)₂, 25.0 C(CH₃)₂, 23.0 (NHCOCH₃), 20.7 (OCOCH₃ at C-4); MS (ESI positive) *m/z* 530.4 [M + Na]⁺.

Synthesis of 4,9-diacetyl 2-benzoyloxycarbonyl-*N*-acetylneuraminic acid 1,7-lactone (7e). To a solution of 1,7-lactone **7d** (100 mg, 0.200 mmol) in dichloromethane (1.5 mL) moist TFA (0.4 μL) was added and the solution was refluxed for 1 h. Then, a weak basic resin (IRA-67) was added to the mixture that was filtered and the solvent evaporated under reduced pressure to give a crude glass that was then purified by column chromatography on silica gel (eluting with AcOEt–hexane, from 95 : 1 then 90 : 10, v/v), to afford pure 4-*O*-acetyl-2-benzoyloxycarbonyl-*N*-acetylneuraminic acid 1,7-lactone (87 mg, 85%) as a glass; [α]_D²⁰ + 17.2 (*c* 1 in MeOH); elemental analysis (Found: C, 53.9; H, 5.3; N, 3.1; C₂₁H₂₅NO₁₁ requires C, 54.0; H, 5.4; N, 3.0%); δ_H (CD₃OD) 7.40–7.31 (5H, overlapping, Ph), 5.25–5.14 (2H, AB system, CH₂Ph), 5.06 (1H, br s, 4-H), 4.74 (s, 1H; 6-H), 4.51 (1H, d, *J*_{7,8} 9.3, 7-H), 4.14–4.10 (1H, br m, 5-H), 4.04 (1H, ddd, *J*_{8,7} 9.3, *J*_{8,9b} 4.0, *J*_{8,9a} 2.9, 8-H), 3.86–3.75 (2H, overlapping, 9a-H and 9b-H), 2.40 (1H, dd, *J*_{3a,3b} 14.6, *J*_{3a,4} 3.8, 1H; 3a-H), 2.28 (1H, br d, *J*_{3b,3a} 14.6, 1H, 3b-H), 2.05 (3H, s, OCOCH₃ at C-4), 2.03 (3H, s, NHCOCH₃); δ_c (CD₃OD) 172.9 (1C, OCOCH₃ at C-4), 170.7 (1C, NHCOCH₃), 167.3 (C-1), 153.5 (PhCH₂OCOO), 136.2, 129.8, 129.7, 129.3 (Ph), 94.7 (C-2), 80.0 (C-7), 73.4 (C-6), 71.6 (PhCH₂OCOO), 71.5 (C-8), 69.5 (C-4), 63.2 (C-9), 50.2 (C-5), 34.3 (C-3), 22.4 (NHCOCH₃), 20.7 (OCOCH₃ at C-4); MS (ESI positive) *m/z* 490.5 [M + Na]⁺, 957.0 [2M + Na]⁺. The obtained 8,9-unprotected lactone (80 mg, 0.172 mmol) in THF (2.0 mL) was treated with trimethyl orthoacetate (66 μL)

containing a catalytic amount of pyridinium *p*-toluenesulfonate (5 mg), for 1 h at 23 °C. At this time, water (0.2 mL) was added, and the mixture stirred for 30 min at room temperature, and then neutralized with a weak basic resin (IRA-67), filtered and evaporated. The residue was chromatographed on silica gel (eluting with AcOEt–MeOH, from 98 : 2 to 95 : 5, v/v), to afford the title compound **7e** (64 mg, 77%) as a glass; [α]_D²⁰ + 14.1 (*c* 1 in MeOH); elemental analysis (Found: C, 54.14; H, 5.4; N, 2.7; C₂₃H₂₇NO₁₂ requires C, 54.2; H, 5.3; N, 2.75%); δ_H (CD₃OD) 7.40–7.31 (5H, overlapping, Ph), 5.23–5.14 (2H, AB system, CH₂Ph), 5.07 (1H, br s, 4-H), 4.70 (1H, s, 6-H), 4.48 (1H, d, *J*_{7,8} 9.1, 7-H), 4.53–4.48 (1H, m, 8-H), 4.29–4.19 (2H, overlapping, 9a-H and 9b-H), 4.21 (1H, br s, 5-H), 2.39 (1H, dd, *J*_{3a,3b} 14.7, *J*_{3a,4} 3.8, 3a-H), 2.25 (1H, br d, *J*_{3a,3b} 14.7, 3b-H), 2.10 (3H, s, OCOCH₃ at C-9), 2.02 (3H, s, OCOCH₃ at C-4), 2.00 (3H, s, NHCOCH₃); δ_c (CD₃OD): 172.9, 172.8, 170.6 (3C, OCOCH₃ at C-9, OCOCH₃ at C-4 and NHCOCH₃), 166.9 (C-1), 153.4 (PhCH₂OCOO), 136.1, 129.8, 129.7, 129.4 (Ph), 94.7 (C-2), 80.4 (C-7), 73.3 (C-6), 71.6 (PhCH₂OCOO), 69.4 (C-8), 69.2 (C-4), 66.2 (C-9), 50.0 (C-5), 34.2 (C-3), 22.4 (NHCOCH₃), 20.8 and 20.7 (2C, OCOCH₃ at C-4 and OCOCH₃ at C-9); MS (ESI positive) *m/z* 532.3 [M + Na]⁺, 1041.8 [2M + Na]⁺.

Synthesis of 4,9-*O*-diacetylated *N*-acetylneuraminic acid 1,7-lactone (4c). The 2-protected 1,7-lactone **7e** (60 mg, 0.120 mmol) was dissolved in ethyl acetate (13 mL) and hydrogenated in the presence of 10% Pd/C (6 mg) for 3 h. The catalyst was then filtered on a pad of Celite that was washed with anhydrous THF. The obtained solution was evaporated under reduced pressure to afford the title compound **4c** (36 mg, 81%) as an amorphous solid; [α]_D²⁰ + 11.2 (*c* 1 in THF); elemental analysis (Found: C, 48.1; H, 5.6; N, 3.8; C₁₅H₂₁NO₁₀ requires C, 48.1; H, 5.6; N, 3.7%); δ_H (DMSO-*d*₆) 8.44 (1H, d, *J*_{NH,5} 7.7, 1H, NHCOCH₃), 7.61 (1H, s, OH at C-2), 5.67 (1H, d, *J*_{OH,8} = 6.3, OH at C-8), 4.85 (1H, br s, H-4), 4.41 (1H, s, 6-H), 4.31 (1H, dd, *J*_{9a,9b} 11.6, *J*_{9a,8} 4.2, 1H, 9a-H), 4.28 (1H, d, *J*_{7,8} 8.9, H-7), 4.20 (1H, dd, *J*_{9b,9a} 11.6, *J*_{8,9a} 6.1, 9a-H), 3.89–3.80 (2H, overlapping, 8-H and 5-H), 2.15 (1H, dd, *J*_{3a,3b} 14.8, *J*_{3b,4} 3.7, 3a-H), 2.05 (3H, s, OCOCH₃), 1.94 (3H, s, OCOCH₃), 1.89 (4H, overlapping, 3b-H and NHCOCH₃); δ_c (DMSO-*d*₆) 170.3, 169.1 (2C, OCOCH₃ at C-4 and OCOCH₃ at C-9), 168.8 (C-1), 168.6 (NHCOCH₃), 90.4 (C-2), 78.2 (C-7), 70.1 (C-8), 68.5 (C-6), 68.2 (C-4), 65.0 (C-9), 47.7 (C-5), 30.3 (C-3), 22.3 (NHCOCH₃), 20.6, 20.5 (2C, OCOCH₃ at C-4 and OCOCH₃ at C-9); MS (ESI negative) *m/z* 374.4 [M – H][–].

Stability tests of lactones 4a–c under neutral and acidic conditions

Tests under aqueous neutral conditions. General procedure. Each pure lactone **4a–c** (20 mg) was dissolved with D₂O (0.7 mL) in a NMR tube at 23 °C and its proton spectrum was acquired at different times: immediately, after 15 min, and after 24 h.

The lactones **4a** and **4b** showed a very poor stability showing, also in the first acquired spectrum, the partial disappearance of the characteristic peaks observed for these lactones in (CD₃)₂SO. In all cases the starting lactone appears to

be completely absent after 24 h without any documentable presence of the parent acids **1a** and **1b**.

Lactone **4c** showed greater stability in water, in fact its spectrum appeared unchanged after 24 h in D₂O.

Tests under aqueous acidic conditions (2 M aq. acetic acid). General procedure. Each 1,7-lactone **4a–c** (20 mg) was dissolved at 23 °C in CH₃COOD (2 M in D₂O) obtained by dissolving anhydrous Ac₂O in D₂O (see the Materials and reagents section) and the test tube was sealed. The solution was heated at 80 °C for 105 min. At this time, each crude reaction mixture was subjected to the ¹H-NMR analyses.

All signals corresponding to 1,7-lactones **4a** and **4b** completely disappeared. In the case of the lactone **4a**, some characteristic signals documented the presence of trace amounts of the parent sialic acid **1a** in the reaction mixture. In contrast, no indication of the presence of the parent acid **1b** could be obtained in the reaction of the lactone **4b**.

The 1,7-lactone **4c** partially survived (around 65%) the acidic hydrolysis and was accompanied by the parent acid **1c** in the final reaction mixture.

Synthesis and characterization of HFB derivatives **8a–c** from the free parent acids **1a–c** and from the 1,7-lactones **4a–c**

General procedure. The appropriate acid or 1,7-lactone (0.05 mmol), dissolved in CH₃CN (0.7 mL), was treated with HFBA (245 μL, 1.0 mmol) at 150 °C for 5 min. An aliquot of the crude mixture was diluted with CH₃CN and directly subjected to GC–MS analyses. Then, the remaining reaction mixture was evaporated under a stream of nitrogen and the crude residue was dissolved in CDCl₃ for the NMR analyses.

Starting from acid **1a and from lactone **4a**.** The crude reaction mixtures obtained starting from the acid **1a** and from the lactone **4a** showed superimposable ¹H- and ¹³C-NMR spectra, identical to that of the compound of structure **8a** reported in the literature^{5f} and in GC–MS analysis, both showed a single peak with the same retention time (*t*_R 6.61 min) and mass spectrum (Fig. 2).

Starting from acid **1b and from lactone **4b**.** The crude residue obtained in the reactions of the acid **1b** and of the lactone **4b** showed superimposable ¹H-NMR spectra, identical to that we reported^{5f} for the compound of structure **8b** and ¹³C-NMR spectrum δ_c (CDCl₃) 173.0 (1C, OCOCH₃ at C-9), 160.9 (C-1), 93.2 (C-2), 76.0 (C-7), 74.4 (C-8), 71.4 (C-6), 70.1 (C-4), 61.1 (C-9), 48.7 (C-5), 32.5 (C-3), 20.1 (1C, OCOCH₃ at C-9). The GC–MS analyses of crude products obtained from compounds **1b** and **4b** showed, in both cases, a single peak with the same retention time (*t*_R 7.24 min) and identical mass spectrum (Fig. 2).

Starting from acid **1c and from lactone **4c**.** The crude residues obtained in the reaction of the acid **1c** and the lactone **4c** showed superimposable ¹H- and ¹³C-NMR spectra that were in agreement with the structure of the 1,7-lactone **8c**: δ_H (CDCl₃): 7.36–7.30 (1H, m, NHCOCH₃), 5.69–5.66 (1H, m, 8-H), 5.51 (1H, br s, 4-H), 4.95–4.88 (2H, overlapping, 7-H and 9a-H), 4.48–4.41 (3H, overlapping, 5-H, 6-H and 9b-H), 2.55 (1H, br d, *J*_{3a,3b} 14.6, 3a-H), 2.41 (1H, dd, *J*_{3b,3a} 14.6, *J*_{3b,4} 2.5, 3b-H), 2.18

(3H, s, OCOCH₃ at C-9), 2.13 (3H, s, OCOCH₃ at C-4); δ_c (CDCl₃) 172.8 and 169.7 (2C, OCOCH₃ at C-4 and OCOCH₃ at C-9), 161.8 (C-1), 93.9 (C-2), 76.2 (C-7), 74.4 (C-8), 71.8 (C-6), 66.6 (C-4), 61.2 (C-9), 49.0 (C-5), 32.8 (C-3), 20.4 and 20.3 (2C, OCOCH₃ at C-4 and OCOCH₃ at C-9). Their GC–MS analysis showed in both cases a single peak with the same retention time (*t*_R 8.30 min) and mass spectrum (Fig. 2).

Inspection by GC–MS analysis of analytical amount of acids **1a–c**, lactones **4a–c** and methyl esters of acids **1a–c**, after derivatization with HFBA

General procedure. The derivatization was performed adopting the protocol reported by Zanetta *et al.*^{1c,3b} avoiding the sometimes reported treatment with diazomethane.^{1c,3b} In separate experiments, samples of the compounds (0.1–1 μg) were dissolved in CH₃CN (200 μL) with the addition of HFBA (25 μL). The vessels were then closed and heated at 150 °C for 5 min. After cooling, the solvent was stripped under a stream of nitrogen. The residue was then dissolved in anhydrous CH₃CN and injected for GC–MS analysis.

Starting from Sias **1a–c and their lactones **4a–c**.** The acids **1a–c** and their 1,7-lactones **4a–c** afforded chromatographic profiles and mass spectra identical to those described above for the 1,7-lactones **8a–c**.

Starting from methyl ester of sialic acid **1a.** Authentic methyl ester of the acid **1a** afforded a reaction product responsible for two chromatographic peaks (at *t*_R 7.80 min and *t*_R 8.84 min respectively) associated with mass spectral fragmentations (A and B, Fig. 3) that completely differ from that reported by Zanetta for sialic acid **1a**, after methylation with diazomethane and perfluoracylation.^{1c} They also differ from that of the lactone **8a** that we obtained starting with the lactone **4a** or with the acid **1a**.

Starting from methyl ester of sialic acid **1b.** Authentic methyl ester of the acid **1b** afforded a single chromatographic peak (*t*_R 9.00 min) associated with a mass spectrum (C, Fig. 3) completely different from that reported by Zanetta for the same acid, after methylation with diazomethane and perfluoracylation.³ It also differs from that we assigned to the lactone **8b**, starting from the lactone **4b** or from the acid **1b**.

Starting from methyl ester of sialic acid **1c.** Authentic methyl ester of the acid **1c** afforded a single chromatographic peak (*t*_R 8.51 min) associated with a mass spectrum (D, Fig. 3) that completely differs from that attributed by Zanetta to acid **1c** after methylation with diazomethane and perfluoracylation.^{1c} It was also different from that we assigned to the lactone **8c** obtained for the lactone **4c** or from the acid **1c**.

Preparation of the untransacylated derivatives **9a–c** by derivatization of the lactones **4a–c** and of the acids **1a–c**

General procedure. Each acid or 1,7-lactone (0.05 mmol) was dissolved in CH₃CN (0.7 mL) and treated with HFBA (245 μL; 1.0 mmol) at 23 °C for 3 h. Then, each reaction mixture was evaporated under a stream of nitrogen and two samples of the crude residue were dissolved in CDCl₃ for the NMR analyses, and in CH₃CN for the GC–MS analyses. Parallel

reactions of the lactones **4a–c** and the acids **1a–c** were also performed at 120 °C for 5 min. After the work-up, the crude reaction mixtures were subjected exclusively to GC–MS analyses.

Preparation of the lactone 9a. Derivatization treatment of the lactone **4a** at 23 °C afforded the lactone **9a**, as a crude product that decomposes in any purification attempt. It showed: δ_{H} (CDCl₃) 6.60 (1H, d, $J_{\text{NH},5}$ 7.9, NH), 5.68 (1H, ddd, $J_{8,7}$ 8.3, $J_{8,9b}$ 3.8, $J_{8,9a}$ 2.1, 8-H), 5.49 (1H, br s, 4-H), 4.99 (1H, dd, $J_{9a,9b}$ 13.0, $J_{9a,8}$ 2.1, 9a-H), 4.86 (1H, d, $J_{8,7}$ 8.3, 7-H), 4.76 (1H, dd, $J_{9b,9a}$ 13.0, $J_{9b,8}$ 3.8, 9b-H), 4.51 (1H, br d, $J_{5,\text{NH}}$ 7.9, 5-H), 4.38 (1H, br s, 6-H), 2.59 (1H, dd, $J_{3a,3b}$ 15.4, $J_{3b,4}$ 2.0, 3a-H), 2.54 (1H, dd, $J_{3b,3a}$ 15.4, $J_{3b,4}$ 3.9, 3b-H) 2.19 (3H, s, NHCOCH₃); δ_{C} (CDCl₃) 173.0 (1C, NHCOCH₃), 160.5 (C-1), 93.4 (C-2), 75.2 (C-7), 73.2 (C-8), 72.1 (C-6), 70.4 (C-4), 63.5 (C-9), 48.1 (C-5), 32.5 (C-3), 22.5 (NHCOCH₃).

Its GC–MS analysis showed a single chromatographic peak (t_{R} 7.47 min) associated with the mass spectrum reported in the figure (Fig. 4). The EI spectrum of the lactone **9a** was identical in all respects to that erroneously attributed by Zanetta *et al.*^{1c} to the congener unesterified at the anomeric hydroxyl.

Performing the derivatization of the lactone **4a** and of the acid **1a**, at 120° for 5 min, we obtained, in both cases, a reaction product responsible for two peaks in GC–MS analysis. We identified the major compound as the lactone **8a**, and the minor one as the lactone **9a**.

Preparation of the lactone 9b. Derivatization treatment of lactone **4b** afforded a product, identified as the crude lactone **9b**, unstable to any attempted purification. It showed: δ_{H} (CDCl₃) 7.04 (d, $J_{\text{NH},5}$ 7.6 Hz, NH), 5.58 (1H, ddd, $J_{8,7}$ 6.6, $J_{8,9b}$ 5.9, $J_{8,9a}$ 2.0, 8-H), 5.54 (1H, br s, 4-H), 4.99 (1H, dd, $J_{9a,9b}$ 13.2, $J_{9a,8}$ 2.0, 9a-H), 4.86 (1H, d, $J_{8,7}$ 6.6, H-7), 4.52–4.45 (2H, overlapping, 5-H and 6-H), 4.41 (1H, dd, $J_{9b,9a}$ 13.2, $J_{9b,8}$ 5.9, 9b-H), 2.60–2.51 (2H, overlapping, 3a-H and 3b-H), 2.18 (3H, s, OCOCH₃ at C-9), 2.14 (3H, s, NHCOCH₃); δ_{C} (CDCl₃) 173.7 (1C, OCOCH₃ at C-9), 173.6 (1C, NHCOCH₃), 161.4 (C-1), 93.3 (C-2), 76.2 (C-7), 75.0 (C-8), 71.8 (C-6), 70.6 (C-4), 61.5 (C-9), 48.3 (C-5), 32.3 (C-3), 22.2 (NHCOCH₃), 20.2 (1C, OCOCH₃ at C-9).

Its GC–MS analysis showed a single chromatographic peak (t_{R} 8.55 min) associated with the mass spectrum reported in the figure (Fig. 4). The mass spectrum of the lactone **9b** was identical in all respects to that erroneously attributed by Zanetta *et al.*^{1c} to the congener unesterified at the anomeric hydroxyl.

Performing the derivatization of the lactone **4b** and of the acid **1b**, at 120° for 5 min, we obtained, in both cases, a reaction product responsible for two peaks in GC–MS analysis. We identified the major compound as the lactone **8b**, and the minor one as the lactone **9b**.

Preparation of the lactone 9c. Derivatization treatment of lactone **4c** afforded a product, identified as the lactone **9c**, unstable to any attempted purification, showing: δ_{H} (CDCl₃) 6.92 (1H, d, $J_{\text{NH},5}$ 7.9, NH), 5.62 (1H, ddd, $J_{8,7}$ 8.5, $J_{8,9b}$ 6.3, $J_{8,9a}$ 2.2, 8-H), 5.30–5.26 (1H, br s, 4-H), 4.92–4.86 (2H, overlapping, 7-H and 9a-H), 4.45 (1H, br s, 6-H), 4.42–4.36 (2H, overlapping, 5-H and 9b-H), 2.49 (1H, br d, $J_{3a,3b}$ 15.0, 3a-H), 2.37 (1H, dd,

$J_{3b,3a}$ 15.0, $J_{3b,4}$ 3.7, 1H, 3b-H), 2.19 (3H, s, COCH₃), 2.18 (3H, s, COCH₃), 2.12 (3H, s, NHCOCH₃); δ_{C} (CDCl₃) 173.4 and 170.3 (3C, OCOCH₃ at C-4, OCOCH₃ at C-9 and NHCOCH₃), 162.3 (C-1), 94.0 (C-2), 76.5 (C-7), 74.9 (C-8), 72.1 (C-6), 67.2 (C-4), 61.6 (C-9), 48.7 (C-5), 32.6 (C-3), 22.1 (NHCOCH₃), 20.4 (2C, COCH₃ at C-9 and COCH₃ at C-4).

Its GC–MS analysis showed a single chromatographic peak (t_{R} 9.74 min) associated with the mass spectrum reported in the figure (Fig. 4). The mass spectrum of the lactone **9c** was identical in all respects to that erroneously attributed by Zanetta *et al.*^{1c} to the congener unesterified at the anomeric hydroxyl.

Performing the derivatization of the lactone **4c** and of the acid **1c**, at 120° for 5 min, we obtained, in both cases, a reaction product responsible for two peaks in GC–MS analysis. We identified the major component of the mixture as the lactone **8c**, and the minor one as the lactone **9c**.

Conclusions

This work demonstrates that the current analytical protocol^{1c,3} for the GC–MS identification of natural Sias and of their 1,7-lactones as HFBs in glycoconjugates has numerous critical flaws. Unfortunately, neglecting several reactions encouraged the misinterpretation of many crucial MS spectra. This caused a detrimental domino effect,^{1b} as many claims in the literature rely on the incorrect identification of Sias with this analytical method.^{1c} For instance we established that 1,7-lactones **4a–c**, although they had been identified with this methodology and reported to have important biological roles also in pathologies,^{3b,3i,4} could not be determined with this approach, because they are decomposed during the hydrolysis step. In fact, those detected 1,7-lactones are merely artifacts formed by lactonization of the corresponding acids, under the acylation conditions used for their derivatization. The acylation with HFBA also causes a second neglected reaction which exchanges the *N*-acetyl group (present in all Sias of the Neu5Ac family) with that of the derivatizing perfluorurated anhydride, to afford different derivatives from those predicted and reported. Neglecting this transformation and overlooking the unexpected failure of the esterification step with diazomethane also caused extensive errors in the identification and quantification of free Sias. While we feel that an urgent correction and improvement of the present analytical protocol^{1c,3} is mandatory, we are assured that the extensive data herein reported will allow a critical revision of the literature in this field.

Acknowledgements

We gratefully acknowledge Prof. Mario Anastasia for the valuable suggestions and his unrelenting encouragement, and Ms Irene Delcarro for her skilled technical assistance.

Notes and references

- 1 (a) X. Chen and A. Varki, *ACS Chem. Biol.*, 2010, **5**, 163–176; (b) T. Angata and A. Varki, *Chem. Rev.*, 2002, **102**, 439; (c) J. P. Zanetta, A. Pons, M. Iwersen, C. Mariller, Y. Leroy, P. Timmerman and R. Schauer, *Glycobiology*, 2001, **11**, 663.
- 2 M. J. Kiefel and M. von Itzstein, *Chem. Rev.*, 2002, **102**, 471–490.
- 3 (a) J. P. Zanetta, P. Timmerman and Y. Leroy, *Glycobiology*, 1999, **9**, 255; (b) D. Bratosin, C. Pali, A. D. Moicean, J. P. Zanetta and J. Montreuil, *Biochimie*, 2007, **89**, 355; (c) I. Popa, A. Pons, C. Mariller, T. Tai, J. P. Zanetta, L. Thomas and J. Portoukalian, *Glycobiology*, 2007, **17**, 367–373; (d) J. P. Zanetta, V. Srinivasan and R. Schauer, *Biochimie*, 2006, **88**, 171–178; (e) A. Bohin, F. Bouchart, C. Richet, S. Kol, Y. Leroy, P. Timmerman, G. Huet, J. P. Bohin and J. P. Zanetta, *Anal. Biochem.*, 2005, **340**, 231; (f) J. P. Zanetta, A. Pons, C. Richet, G. Huet, P. Timmerman, Y. Leroy, A. Bohin, J. P. Bohm, P. A. Trinel, D. Poulain and J. Hofsteenge, *Anal. Biochem.*, 2004, **329**, 199; (g) T. Bulai, D. Bratosin, A. Pons, J. Montreuil and J. P. Zanetta, *FEBS Lett.*, 2003, **534**, 185; (h) A. Pons, C. Richet, C. Robbe, A. Herrmann, P. Timmerman, G. Huet, Y. Leroy, I. Carlstedt, C. Capon and J. P. Zanetta, *Biochemistry*, 2003, **42**, 8342; (i) I. Popa, J. P. Zanetta, J. Portoukalian and L. Thomas, *J. Invest. Dermatol.*, 2002, **118**, 903; (j) A. Rinninger, C. Richet, A. Pons, G. Kohla, R. Schauer, H. C. Bauer, J. P. Zanetta and R. Vlasak, *Glycoconjugate J.*, 2006, **23**, 73–84.
- 4 (a) C. Cebo, T. Dambrouck, E. Maes, C. Laden, G. Strecker, J. C. Michalski and J. P. Zanetta, *J. Biol. Chem.*, 2001, **276**, 5685; (b) C. Cebo, G. Vergoten and J. P. Zanetta, *Biochim. Biophys. Acta*, 2002, **1572**, 422.
- 5 (a) P. Allevi, E. A. Femia, M. L. Costa, R. Cazzola and M. Anastasia, *J. Chromatogr., A*, 2008, **1212**, 98; (b) P. Rota, I. S. Agnolin, P. Allevi and M. Anastasia, *Eur. J. Org. Chem.*, 2012, 2508; (c) P. Rota, P. Allevi, I. S. Agnolin, R. Mattina, N. Papini and M. Anastasia, *Org. Biomol. Chem.*, 2012, **10**, 2885; (d) P. Rota, P. Allevi, R. Colombo, M. L. Costa and M. Anastasia, *Angew. Chem.*, 2010, **122**, 1894; P. Rota, P. Allevi, R. Colombo, M. L. Costa and M. Anastasia, *Angew. Chem., Int. Ed.*, 2010, **49**, 1850–1853; (e) P. Rota, P. Allevi, M. L. Costa and M. Anastasia, *Tetrahedron: Asymmetry*, 2010, **21**, 2681; (f) P. Rota, P. Allevi, R. Mattina and M. Anastasia, *Org. Biomol. Chem.*, 2010, **8**, 3771; (g) P. Allevi, P. Rota, R. Scaringi, R. Colombo and M. Anastasia, *J. Org. Chem.*, 2010, **75**, 5542; (h) P. Allevi, M. Anastasia, M. L. Costa and P. Rota, *Tetrahedron: Asymmetry*, 2011, **22**, 338; (i) R. Colombo, M. Anastasia, P. Rota and P. Allevi, *Chem. Commun.*, 2008, 5517, DOI: 10.1039/c5cc90091c.
- 6 (a) N. Sugiyama, K. Sugai, N. Yamada, M. Goto, C. Ban, K. Furuhata, H. Takayanagi and H. Ogura, *Chem. Pharm. Bull.*, 1988, **36**, 1147; (b) S. Sato, K. Furuhata and H. Ogura, *Chem. Pharm. Bull.*, 1988, **36**, 4678.
- 7 (a) H. Ogura, K. Furuhata, S. Sato, K. Anazawa, M. Itoh and Y. Shitori, *Carbohydr. Res.*, 1987, **167**, 77–86; (b) A. Hasegawa, T. Murase, M. Ogawa, H. Ishida and M. Kiso, *J. Carbohydr. Chem.*, 1990, **9**, 415.
- 8 A. Bianco, C. Melchioni, G. Ortaggi, P. Romagnoli and M. Brufani, *J. Mol. Catal. B: Enzym.*, 1997, **3**, 209.